Trial Profile
A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week Study to Assess the Efficacy and Safety of Mesalamine Granules 750 mg and 1,500 mg Capsules Administered Once Daily in the Treatment of Irritable Bowel Syndrome With Diarrhea
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2019
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 24 Oct 2012 Results presented at the American Journal of Gastroenterology conference: 77th Annual Scientific Meeting of the American College of Gastroenterology.
- 22 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.